NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) — According to a new research report titled “Diabetic Foot Ulcer Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Diabetic foot ulcer currently exhibits a strong pipeline with 27 drug candidates.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis/report-sample
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where neuropathy dominates and neuroischemic foot where occlusive vascular disease is the main factor. Diabetic neuropathy, peripheral artery disease and consequent trauma of the foot are the major risk factors for diabetic foot ulcer. The motor and sensory nerve damage can cause muscle weakness, paresis and atrophy in diabetic patients. Diabetic foot ulcer can be assessed by physical examination of the skin for the vascular, neurological, and musculoskeletal systems. Additionally, this examination also involves the assessment of perception of superficial pain, and temperature. Neuropathic disability score is assessed to evaluate the risk of occurrence of neuropathic ulceration.
Access Report Summary at: https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Most of the innovations in technology have been producing novel therapies for the treatment of diabetic foot ulcer. NOx is an advanced wound care technology invented by Edixomed Ltd, that provides the important moist environment, which aids in healing and absorbs wound exudate that generates nitric oxide.
Significant growth in the therapeutic pipeline of diabetic foot ulcer is attributed to increasing collaboration between educational institutes, associations and pharma companies as well as biotech companies. For instance, in March 2016, Microbion Corporation entered into an agreement with Haisco Pharmaceutical Group to develop and commercialize Microbion’s drug candidate for the treatment of chronic wounds in China and related territories.
Make Enquiry Before Buying: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-foot-ulcers-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of diabetic foot ulcer include Lakewood Amedex, Inc., Edixomed Ltd., CardioVascular BioTherapeutics Inc. and others.
Browse Related Reports:
Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis – https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis
Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis – https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com